Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 33
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Neurobiol Aging ; 19(3): 201-4, 1998.
Artículo en Inglés | MEDLINE | ID: mdl-9661994

RESUMEN

Alzheimer's disease (AD) brains display intense microglial immunoreactivity in the area of senile plaques, suggesting that amyloid beta-protein may stimulate microglial infiltration. The activated microglia may modulate an immune response in the brain. Non-steroidal anti-inflammatory drugs (NSAIDs) are candidate therapeutics for AD because their effects on immune system components may influence the course of the disease. The present study examined the effects of an NSAID (indomethacin) on amyloid beta-protein-induced microglial infiltration. Amyloid beta-protein was chronically infused into rat lateral ventricles for 2 weeks. Extracellular amyloid beta-protein deposited along the lining and diffused into the tissue surrounding the lateral ventricle. Immunocytochemical staining showed that animals receiving amyloid beta-protein exhibited dramatic microglial response when compared to vehicle-infused rats. Activated microglia surrounded immunopositive amyloid beta-protein deposits, but this response was significantly attenuated in animals receiving either concurrent i.c.v. or subcutaneous (s.c.) treatment with indomethacin. These results suggest that chronic amyloid beta-protein infusion induces the proliferation of activated microglia and that indomethacin may be an effective treatment for inhibiting microglial proliferation.


Asunto(s)
Péptidos beta-Amiloides/antagonistas & inhibidores , Antiinflamatorios no Esteroideos/farmacología , Indometacina/farmacología , Microglía/efectos de los fármacos , Péptidos beta-Amiloides/farmacología , Animales , Antiinflamatorios no Esteroideos/administración & dosificación , Encéfalo/patología , Química Encefálica/efectos de los fármacos , Inmunohistoquímica , Indometacina/administración & dosificación , Inyecciones Intraventriculares , Masculino , Ratas
2.
Cell Mol Neurobiol ; 14(5): 425-37, 1994 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-7621505

RESUMEN

1. The amyloid precursor protein (APP) is widely distributed among eukaryotic cells, however, its precise role in cellular functioning is not fully clarified. APP is glycoprotein membrane constituent and it may facilitate membrane associated functions. 2. The aim of the present study was to examine the possibility that APP may play a role in mediating cellular trophic responses. The methods made use of an antisense oligonucleotide that was prepared to the 5' terminus of APP and shown specifically to reduce the level of APP isoforms. 3. In sequential mixing experiments it was observed that the APP antisense oligonucleotide did not significantly modify the trophic response of PC12 cells pretreated with nerve growth factor (NGF). However, pretreatment of cells with the antisense oligonucleotide diminished NGF-induced increases in cellular size and neurite length. 4. These observations suggest that APP may play a role in modulating the trophic response. The combined use of APP antisense oligonucleotides and neurotrophic agents may find clinical utility in the treatment of Alzheimer-type dementia since it is known that NGF normally causes increases in APP levels.


Asunto(s)
Amiloide/antagonistas & inhibidores , Factores de Crecimiento Nervioso/farmacología , Oligonucleótidos Antisentido/farmacología , Células PC12/efectos de los fármacos , Precursores de Proteínas/antagonistas & inhibidores , Enfermedad de Alzheimer/tratamiento farmacológico , Amiloide/genética , Amiloide/fisiología , Animales , Secuencia de Bases , Tamaño de la Célula/efectos de los fármacos , Procesamiento de Imagen Asistido por Computador , Datos de Secuencia Molecular , Factores de Crecimiento Nervioso/antagonistas & inhibidores , Neuritas/efectos de los fármacos , Neuritas/ultraestructura , Priones , Precursores de Proteínas/genética , Precursores de Proteínas/fisiología , Ratas , Tionucleótidos/farmacología
3.
Mol Neurobiol ; 9(1-3): 107-13, 1994.
Artículo en Inglés | MEDLINE | ID: mdl-7888086

RESUMEN

We evaluated the efficacy of murine monoclonal antibodies (MAbs) targeted to the A beta amyloid of Alzheimer's disease for development of procedures for the in vivo identification of amyloid angiopathy (AA). MAbs to A beta were prepared and screened for effectiveness in visualizing AA and neuritic plaques in postmortem AD brain sections. They were assessed again after enzymatic cleavage to produce Fab fragments and after labeling with technetium-99m (99mTc) using a diamide dimercaptide ligand system. Modified and radiolabeled Fab fragments retained activity and specificity toward amyloid-laden blood vessels and neuritic plaques. A highly specific murine MAb, 10H3, was identified and characterized that fulfills criteria necessary for the development of an in vivo diagnostic imaging agent. Toxicity studies in rats showed the MAb to be safe. Biodistribution studies in mice demonstrated desirable properties for use as an imaging agent. Expansion and adaptation of these strategies may provide the methods and materials for the noninvasive analysis of AA in living patients, and permit assessment of the contribution of AA to the clinical and pathological features of AD.


Asunto(s)
Enfermedad de Alzheimer/diagnóstico por imagen , Amiloide/análisis , Anticuerpos Monoclonales , Angiopatía Amiloide Cerebral/diagnóstico por imagen , Anciano , Anciano de 80 o más Años , Secuencia de Aminoácidos , Animales , Química Encefálica , Citometría de Flujo , Humanos , Inmunohistoquímica , Masculino , Ratones , Ratones Endogámicos BALB C , Datos de Secuencia Molecular , Radioinmunodetección , Ratas , Ratas Sprague-Dawley
4.
Scanning Microsc ; 8(2): 325-35; discussion 335-6, 1994.
Artículo en Inglés | MEDLINE | ID: mdl-7535473

RESUMEN

The amyloid precursor protein (APP) is an integral membrane component of eukaryotic cells. A variety of research approaches have addressed the contribution of the beta amyloid peptide region of the APP to neuritic plaque structure and formation in the Alzheimer disease brain as well as the relationship between beta amyloid accumulation and the occurrence of dementia. However, there is limited information available concerning the cellular consequences of amyloid deposition. The present studies were undertaken to investigate the relationship between beta amyloid and intercellular junctions. Transfected PC12 cell lines, that overexpress the beta amyloid peptide, exhibit structural and functional alterations at the cell surface and tend to form aggregates more readily than normal control cells. Intermediate junctions were the most common intercellular interactions of both normal and transfected cells. However, the control and transfected cells differed since areas of continuous and extensive junctions were readily seen in transfected cells and infrequently seen in control cells. The data suggest that excess accumulation of beta amyloid is associated with the junctional apparatus and may be related to increased intercellular adhesion.


Asunto(s)
Péptidos beta-Amiloides/metabolismo , Actinas/metabolismo , Péptidos beta-Amiloides/inmunología , Animales , Membrana Celular/ultraestructura , Epítopos , Inmunohistoquímica , Uniones Intercelulares/ultraestructura , Microscopía Electrónica , Células PC12 , Ratas , Coloración y Etiquetado , Distribución Tisular , Transfección
5.
Brain Res ; 621(1): 145-9, 1993 Sep 03.
Artículo en Inglés | MEDLINE | ID: mdl-8221067

RESUMEN

Deposition of beta/A4 amyloid in brain is a defining characteristic of Alzheimer disease (AD); however, the extent to which amyloid deposits may interfere with normal cellular processes is incompletely understood. We examined this issue by means of PC12 cells. After transfection with DNA coding for 97 amino acids of the beta/A4 C-terminal region of the amyloid precursor protein, beta/A4 antigen was visible at the cell membrane. We report that normal unstimulated PC12 cells exhibit ruffling activity at the cell surface when plated on a plastic substrate. Relative to control cells, however, those that over-expressed the beta/A4 C-terminal peptide had significantly higher levels of ruffling activity, suggesting a structural and/or functional membrane modification. Similar cellular alterations, if present, in Alzheimer brain cells, may indicate disturbances in membrane-associated functions, including intercellular communication.


Asunto(s)
Enfermedad de Alzheimer/metabolismo , Enfermedad de Alzheimer/patología , Péptidos beta-Amiloides/biosíntesis , Membrana Celular/ultraestructura , Proteínas del Tejido Nervioso/biosíntesis , Animales , Membrana Celular/fisiología , Células PC12/metabolismo
6.
Mol Chem Neuropathol ; 18(1-2): 99-113, 1993.
Artículo en Inglés | MEDLINE | ID: mdl-8466596

RESUMEN

The beta/A4 region of the amyloid precursor protein (APP) accumulates in brains of victims of Alzheimer disease (AD) where it is a major component of senile plaques. We examined the pathophysiological consequences of overexpression of the beta/A4-C-terminal DNA in PC12 cells. Serum-free conditioned media (SFCM) from positive transfectants stimulated control PC12 cells to extend neurites and increase in size. Unlike the factor that affected cell size, neurite lengthening activity was significantly decreased after immunoabsorption with anti-beta/A4 monoclonal antibodies (MAb) and changes in pH. The data support the view that among the consequences of beta/A4-C-terminal DNA overexpression in PC12 cells is the release of factors that stimulate nontransfected cells to undergo morphological transformations that include differentiation to a neuronal phenotype. It is hypothesized that similar activities that may contribute to the molecular pathophysiology of the disorder may be present in the AD brain.


Asunto(s)
Precursor de Proteína beta-Amiloide/biosíntesis , ADN/biosíntesis , Adsorción , Precursor de Proteína beta-Amiloide/genética , Animales , Secuencia de Bases , Southern Blotting , Adhesión Celular , Diferenciación Celular , Medios de Cultivo Condicionados , ADN/genética , Reacción de Inmunoadherencia , Datos de Secuencia Molecular , Células PC12 , Fenotipo , Transfección
7.
Brain Res ; 599(1): 64-72, 1992 Dec 18.
Artículo en Inglés | MEDLINE | ID: mdl-1493551

RESUMEN

Deposition of beta/A4 amyloid in Alzheimer disease (AD) brain parenchyma and vasculature occurs by mechanisms that are currently undefined. Similarly the potential consequences of amyloid accumulation for disrupting cellular integrity have not been addressed in detail. To investigate the possible significance of amyloid deposits for cellular viability, PC12 cells were permanently transfected with DNA coding for the beta/A4-C terminal region of the amyloid precursor protein. The DNA represented 97 amino acids of the amyloid precursor protein of which 40 amino acids were derived from the beta/A4 region. Transfected clonal cell lines and controls were examined at both the light and electron microscopic levels for morphological abnormalities. beta/A4 amyloid accumulated in the cell membrane where the peptide was located at cellular processes resembling blebs and microvilli. These specialized structures at the cell surface were over-abundant in transfected cells that overexpressed the beta/A4 peptide but not in controls. Membranous processes may be involved in the delivery of the beta/A4 peptide to the external surface of the cell of origin and release into the extracellular space. Similar surface features of cells in the AD brain, should they occur, may indicate a role for membrane-associated processes in the pathophysiology of the disorder.


Asunto(s)
Precursor de Proteína beta-Amiloide/biosíntesis , Membrana Celular/ultraestructura , Neuritas/ultraestructura , Precursor de Proteína beta-Amiloide/genética , Animales , Membrana Celular/metabolismo , ADN/genética , ADN/metabolismo , Humanos , Microscopía Electrónica , Células PC12 , Transfección
8.
J Nucl Med ; 33(12): 2184-9, 1992 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-1460513

RESUMEN

We evaluated the efficacy of murine monoclonal antibodies (Mabs) targeted to beta/A4 amyloid for development of procedures for the in vivo identification of amyloid angiopathy (AA) in Alzheimer's disease (AD). Mabs to beta/A4 amyloid were prepared and screened for effectiveness in visualizing AA and senile plaques in postmortem AD brain sections. They were assessed again after enzymatic cleavage to produce Fab fragments and after labeling with 99mTc using a diamide dimercaptide ligand system. Modified and radiolabeled Fab fragments retained activity and specificity towards amyloid-laden blood vessels and senile plaques. A highly specific murine Mab, 10H3, was identified and characterized that fulfills criteria necessary for the development of a diagnostic imaging agent. Expansion and adaptation of these strategies may provide the methods and materials for the noninvasive analysis of AA in living patients, and permit assessment of the contribution of AA to the clinical and pathological features of AD.


Asunto(s)
Enfermedad de Alzheimer/patología , Péptidos beta-Amiloides/inmunología , Anticuerpos Monoclonales/biosíntesis , Encéfalo/patología , Angiopatía Amiloide Cerebral/diagnóstico por imagen , Radioinmunodetección , Anciano , Anciano de 80 o más Años , Animales , Especificidad de Anticuerpos , Humanos , Fragmentos Fab de Inmunoglobulinas , Masculino , Ratones , Tecnecio
9.
Proc Natl Acad Sci U S A ; 89(15): 7090-4, 1992 Aug 01.
Artículo en Inglés | MEDLINE | ID: mdl-1496005

RESUMEN

Alzheimer disease patients exhibit irregularities in the patterns of normally circadian (daily) rhythms. Alzheimer-type pathology has been reported in the hypothalamus and in the suprachiasmatic nuclei, the putative site of the circadian oscillator. We examined the relationship between the neuropathology of Alzheimer disease, as modeled by an animal system, and circadian dysregulation by grafting genetically transformed cells that overexpress beta/A4 amyloid into the suprachiasmatic nuclei of adult rats. Grafts of beta/A4-positive cells, but not of control cells, significantly altered the pattern of activity of implanted rats. Although experimental conditions included light-dark cycles that normally tend to drive rats to 24-h rhythms, animals with grafts of beta/A4-positive cells showed abnormally high levels of activity during the light phase in addition to a disrupted circadian pattern. Periodogram analysis demonstrated significant rhythms outside of a circadian range. The body temperature rhythm of these animals was also weak 6 weeks after grafting; however, unlike activity patterns, body temperature regained a circadian period by 8 weeks after cell implantation. These data indicate that disruption of circadian activity is a behavioral measure of the consequences of beta/A4 accumulation in brain implants.


Asunto(s)
Enfermedad de Alzheimer/fisiopatología , Péptidos beta-Amiloides/genética , Péptidos beta-Amiloides/fisiología , Trasplante de Tejido Encefálico/fisiología , Encéfalo/fisiología , Ritmo Circadiano , Péptidos beta-Amiloides/análisis , Animales , Anticuerpos Monoclonales , Oscuridad , Femenino , Humanos , Inmunohistoquímica , Luz , Actividad Motora , Células PC12 , Ratas , Ratas Endogámicas , Núcleo Supraquiasmático/fisiología , Transfección
10.
J Mol Neurosci ; 3(3): 111-25, 1992.
Artículo en Inglés | MEDLINE | ID: mdl-1627458

RESUMEN

Alzheimer's Disease (AD), a disorder of unknown etiology, is the most common form of adult-onset dementia and is characterized by severe intellectual deterioration. The definitive diagnosis of AD is made by postmortem examination of the brain, which reveals large quantities of neurofibrillary tangles (NFT) and senile plaques within the parenchyma. The NFT are composed of paired helical filaments associated with several cytoskeletal proteins. The primary protein component of senile plaques is beta/A4 amyloid, a 42-43 amino acid peptide derived from a much larger molecule, the amyloid precursor protein (APP). Vascular beta/A4 amyloidosis is also prevalent in the disease. The mechanism by which beta/A4 amyloid accumulates in the AD brain is unknown. Recent research has demonstrated that the precursor molecule, APP, is a transmembrane protein with a large extracytoplasmic domain, a membrane spanning region that includes the portion that gives rise to beta/A4 amyloid, and a short intracytoplasmic domain. The precursor has multiple forms among which are those that differ by a variable length insert within the extracytoplasmic domain. The insert has sequence homology to the family of Kunitz protease inhibitor proteins. Cellular and animal models have been developed to study the nature of APP processing and the biological and behavioral consequences of beta/A4 amyloidosis. The results of such studies indicate that the normal processing of APP involves enzymatic cleavage of the molecule within the beta/A4 amyloid region, thus preventing the accumulation of beta/A4 in the normal brain. The factors leading to abnormal processing of APP, and consequent beta/A4 amyloid accumulation within the AD brain, have yet to be identified. In cell culture, the biological effects associated with beta/A4 amyloid include neurotrophic and neurotoxic activities, while the peptide has also been shown to have dramatic behavioral effects in animal models.


Asunto(s)
Enfermedad de Alzheimer/metabolismo , Amiloide/metabolismo , Enfermedad de Alzheimer/genética , Amiloide/genética , Péptidos beta-Amiloides/genética , Péptidos beta-Amiloides/metabolismo , Precursor de Proteína beta-Amiloide/genética , Precursor de Proteína beta-Amiloide/metabolismo , Animales , Encéfalo/metabolismo , Encéfalo/patología , Arterias Cerebrales/metabolismo , Arterias Cerebrales/patología , Proteínas del Citoesqueleto/metabolismo , Modelos Animales de Enfermedad , Expresión Génica , Humanos , Ratones , Ovillos Neurofibrilares/metabolismo , Procesamiento Proteico-Postraduccional , ARN Mensajero/biosíntesis
11.
Neuroscience ; 42(3): 651-60, 1991.
Artículo en Inglés | MEDLINE | ID: mdl-1956514

RESUMEN

The studies described have sought to determine what, if any, relationship exists between axons and the senile plaque, a hallmark histopathological feature of Alzheimer's disease. A double stain was performed on both early and late Alzheimer frontal cortex tissues in order to examine the interaction between axons stained with antibodies against the 200,000 mol. wt neurofilament subunit (NFP-200) of the axon cytoskeleton and Thioflavin-S, a fluorescent dye that stains plaques. Serial photomicrographs of plaques were taken and axon and plaque profiles were three-dimensionally reconstructed. Analysis of computer-processed images revealed that there were fewer axons within plaques than in regions lying one and two plaque distances away. When axons were observed passing through plaques, swelling and disruption of normal morphology was frequently present. Statistical analyses of axon counts within and around placques showed a gradient of axon density, with increased numbers occurring at progressive distances from the placque. Similar patterns were seen for early and late stages of the disease. The results of this study indicate that disruption of the axonal cytoskeleton may occur within the regions occupied by plaques.


Asunto(s)
Enfermedad de Alzheimer/patología , Axones/patología , Amiloide/análisis , Benzotiazoles , Citoesqueleto/ultraestructura , Técnica del Anticuerpo Fluorescente , Colorantes Fluorescentes , Lóbulo Frontal/patología , Humanos , Procesamiento de Imagen Asistido por Computador , Proteínas del Tejido Nervioso/análisis , Proteínas de Neurofilamentos/análisis , Proteínas de Neurofilamentos/inmunología , Tiazoles
12.
J Geriatr Psychiatry Neurol ; 3(3): 139-45, 1990.
Artículo en Inglés | MEDLINE | ID: mdl-2126439

RESUMEN

The mechanism by which the A4 (beta-amyloid) domain of the Alzheimer amyloid precursor protein (APP) is deposited in plaques is unknown, and limited information is available concerning the extent to which other APP sites are associated with plaques. To address these issues, we prepared antiserum to a peptide adjacent to the N-terminus of the APP (referred to as N1) and examined its distribution in brain relative to A4 by double-immunostaining techniques. Anti-N1 localized to both neurons and glia in control and Alzheimer patients. In the Alzheimer brain, anti-N1 detected plaques. Quantitation revealed that 85% of thioflavin-positive plaques, and 91% of A4-positive plaques were also N1 positive. Double-staining methods directly demonstrated colocalization of distant APP sites. The data suggest that suggest that proposed mechanisms for amyloid deposition during plaque formation must take into account the extracytoplasmic domain, in addition to the A4 region, rather than be confined exclusively to the A4 site.


Asunto(s)
Enfermedad de Alzheimer/inmunología , Péptidos beta-Amiloides/análisis , Encéfalo/inmunología , Neurofibrillas/inmunología , Inhibidores de Proteasas/análisis , Precursores de Proteínas/análisis , Anciano , Enfermedad de Alzheimer/metabolismo , Enfermedad de Alzheimer/patología , Péptidos beta-Amiloides/inmunología , Precursor de Proteína beta-Amiloide , Anticuerpos Monoclonales , Química Encefálica , Femenino , Humanos , Inmunohistoquímica , Masculino , Proteínas de la Membrana/análisis , Proteínas del Tejido Nervioso/análisis , Neurofibrillas/química , Neurofibrillas/patología , Precursores de Proteínas/inmunología
13.
J Psychiatr Res ; 24(1): 37-50, 1990.
Artículo en Inglés | MEDLINE | ID: mdl-2195164

RESUMEN

Since the detailed molecular events leading to the formation of amyloid-containing senile plaques of the Alzheimer's disease (AD) brain are incompletely understood, the present studies were undertaken to address this issue using a combination of molecular and cytochemical approaches. Amyloid precursor protein riboprobes containing the A4 (beta-amyloid) domain were applied to cortex using the in situ hybridization method to examine the distribution of neuronal amyloid mRNA in relation to the laminar pattern of amyloid deposition and the localization of plaques. The derived data indicated that high levels of amyloid mRNA can be synthesized by AD cortical neurons that appeared to be morphologically intact. The distribution of these cells was not coincident with the cortical laminar pattern that is typical of amyloid deposits observed after immunostaining with anti-A4 monoclonal antibodies. Further, there was no obvious relationship between neurons containing abundant amyloid mRNA and the distribution of plaques identified by thioflavin S staining. While the neuronal synthesis of amyloid may be a significant factor at some point during plaque formation, it may not be the exclusive determinant. The possibility is raised that processes affecting secretion, diffusion, and/or transport of amyloid away from neuronal or non-neuronal cells of origin to sites of deposition may be meaningful aspects of the molecular pathology of Alzheimer's disease.


Asunto(s)
Enfermedad de Alzheimer/patología , Amiloide/biosíntesis , Lóbulo Frontal/patología , Sondas ARN , ARN Mensajero/metabolismo , Anciano , Péptidos beta-Amiloides , Anticuerpos Monoclonales , Autorradiografía , Humanos , Neurofibrillas/ultraestructura , Neuronas/patología
14.
J Neurochem ; 53(3): 953-61, 1989 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-2668446

RESUMEN

Immunohistological and biochemical studies were initiated to determine whether or not neural membrane components were associated with degenerative changes characteristic of Alzheimer's disease (AD). Monoclonal antibody A2B5, developed against embryonic chick retinal cells and previously shown to react with neural surface gangliosides, was applied to formalin-fixed sections of control and AD brain tissue. Frontal cortex and hippocampus of AD cases exhibited high levels of A2B5 immunoreactivity within those neurons undergoing neurofibrillary degeneration. Neuritic processes associated with senile plaques were also highly reactive with the A2B5 antibody. The amount of gangliosides and their pattern after HPTLC were the same in control and AD cases. However, the unexpected observation was made that the A2B5 antibody reacted with human brain sulfatides in addition to the expected reactivity with minor gangliosides. The average level of sulfatides in AD brain was significantly higher than in normal controls. The data support the involvement of one or more membrane components with neurodegeneration in the Alzheimer brain.


Asunto(s)
Enfermedad de Alzheimer/metabolismo , Anticuerpos Monoclonales , Antígenos de Superficie/análisis , Química Encefálica , Membrana Celular/análisis , Gangliósidos/análisis , Retina/inmunología , Sulfoglicoesfingolípidos/análisis , Enfermedad de Alzheimer/inmunología , Enfermedad de Alzheimer/patología , Animales , Antígenos de Superficie/inmunología , Benzotiazoles , Embrión de Pollo , Técnica del Anticuerpo Fluorescente , Lóbulo Frontal/análisis , Lóbulo Frontal/inmunología , Hipocampo/análisis , Hipocampo/inmunología , Histocitoquímica , Humanos , Técnicas para Inmunoenzimas , Ratones , Neurofibrillas/análisis , Tiazoles/análisis
15.
Proc Natl Acad Sci U S A ; 86(1): 337-41, 1989 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-2563163

RESUMEN

Among the major obstacles to clarifying molecular mechanisms involved in amyloid metabolism in Alzheimer disease has been the unavailability of laboratory models for this uniquely human disorder. The present studies were aimed at establishing genetically engineered cell lines that overexpress amyloid immunoreactivity and that may be relevant to amyloid accumulation in the Alzheimer disease brain. We used cloned amyloid cDNA that contains a region encoding A4 (beta-polypeptide) amino acids along with recently developed tumor virus vectors derived from simian virus 40 to prepare transformed cells. After transient and permanent transfection, a variety of cell types overexpressed A4 immunoreactivity that was detected by highly specific monoclonal antibodies. We observed that the use of an amyloid subdomain containing the A4 region, but lacking the sequence of a Kunitz-type protease inhibitor found in amyloid precursor protein variants, was sufficient to obtain cells that overproduced an A4 epitope. The transformed cells were readily propagated in culture and may provide an experimental medium to elucidate aspects of the molecular pathogenesis of Alzheimer disease. The cellular models may also serve as tools for deriving potentially useful therapeutic agents.


Asunto(s)
Enfermedad de Alzheimer/patología , Amiloide/genética , Transformación Celular Viral , Modelos Biológicos , Precursores de Proteínas/genética , Virus 40 de los Simios/genética , Secuencia de Aminoácidos , Amiloide/análisis , Precursor de Proteína beta-Amiloide , Amiloidosis/etiología , Amiloidosis/patología , Animales , Secuencia de Bases , Encéfalo/metabolismo , Encéfalo/patología , Línea Celular , Clonación Molecular , Genes , Vectores Genéticos , Humanos , Datos de Secuencia Molecular , Precursores de Proteínas/análisis
16.
Proc Natl Acad Sci U S A ; 86(2): 745-9, 1989 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-2563169

RESUMEN

Information concerning the distribution of various subdomains of the amyloid precursor protein (APP) in brain may illuminate aspects of the normal metabolism of this membrane-associated protein, as well as putative abnormal processing that may occur in Alzheimer disease (AD). We prepared affinity-purified antibody, P2, against an extracytoplasmic APP site and applied it, along with monoclonal antibodies to the beta-peptide, or A4 region, in conjunction with selective cytochemical staining methods, to control and AD tissues. The following was noted: (i) in contrast to A4 epitopes, which are easily demonstrable primarily in extracellular senile plaques of AD patients, the extracytoplasmic P2 antigen was found in association with neurons, glia, and blood vessels in both normal and AD prefrontal cortex; (ii) a subset of senile plaques contained both A4 and P2 antigens; (iii) in some instances, P2 antigen occurred as an extracellular deposit in the absence of A4; (iv) the P2 antigen, but not A4, was also associated with corpora amylacea. In addition to identifying the unique cellular distribution of the APP extracytoplasmic antigen, the results support the view that a segment of this domain undergoes processing and deposition at extracellular sites, including a subset of senile plaques.


Asunto(s)
Enfermedad de Alzheimer/metabolismo , Amiloide/análisis , Química Encefálica , Precursores de Proteínas/análisis , Enfermedad de Alzheimer/patología , Precursor de Proteína beta-Amiloide , Anticuerpos Monoclonales , Astrocitos/análisis , Técnica del Anticuerpo Fluorescente , Humanos , Immunoblotting , Técnicas para Inmunoenzimas , Inmunohistoquímica
18.
Neuroscience ; 33(3): 483-8, 1989.
Artículo en Inglés | MEDLINE | ID: mdl-2700016

RESUMEN

A recent study reported that Alzheimer senile plaques immunostained with monoclonal antibodies against the A4 (beta-amyloid) region of the amyloid precursor protein show gradients of density (Majocha R. E., Benes F. M., Reifel R. L., Rodenrys A. M. and Marotta C. A., Proc. natn. Acad. Sci. U.S.A. 85, 6182-6186, 1988). Although more than one explanation was suggested for this observation, the possible involvement of a diffusional process during plaque maturation was considered. In order to examine this hypothesis, specimens from prefrontal cortex, entorhinal area and hippocampal formation were immunoprocessed in a similar fashion and subjected to quantitative microdensitometric analyses of A4 amyloid reaction product. All plaques in the three brain areas examined showed a curvilinear relationship between the area of amyloid reaction product (expressed in pixel counts) and optical density (expressed as each of six grey scale levels). There was an increase in the area of amyloid at progressively lower density levels. When the area of amyloid reaction product at each density level was correlated with the overall size of individual plaques, it was found that there was a striking increase in the correlation coefficients at progressively lower grey scale levels, with r = 0.853 at the lowest level examined. When a second order derivation of these correlations was performed by expressing individual r-values with respect to an optical density index, an asymptotic relationship resulted with the lowest density levels showing an increasingly sharp rise toward unity. These data are consistent overall with a model for plaque maturation that involves diffusion of amyloid protein through the extracellular space from focal regions of high density where synthesis and/or release may occur.


Asunto(s)
Enfermedad de Alzheimer/metabolismo , Amiloide/metabolismo , Amiloidosis/metabolismo , Neurofibrillas/patología , Enfermedad de Alzheimer/patología , Péptidos beta-Amiloides , Amiloidosis/patología , Anticuerpos Monoclonales , Encéfalo/metabolismo , Encéfalo/patología , Humanos , Procesamiento de Imagen Asistido por Computador , Inmunohistoquímica
19.
Neurosci Lett ; 92(3): 291-7, 1988 Oct 17.
Artículo en Inglés | MEDLINE | ID: mdl-2462197

RESUMEN

The high molecular weight subunit of neurofilaments (NF-H) in mouse NB2a/d1 neuroblastoma cells is extensively phosphorylated and exhibits an apparent molecular weight of 200 kDa by SDS gel electrophoresis. In this study, we observed that extensively phosphorylated NF-H variants exist as both Triton-soluble and -insoluble forms, which display different cellular distributions. Perikarya and neurites of differentiated NB2a/d1 cells were immunostained by a polyclonal antiserum (anti-NF-H) that specifically recognizes the extensively phosphorylated NF-H forms and a monoclonal antibody (SMI-31) that recognizes phosphorylated epitopes of neurofilament proteins (NFPs). When cells were extracted with Triton X-100 to remove soluble proteins, however, only axonal neurites remained immunoreactive. Immunoblot analyses established the specificity of anti-NF-H and SMI-31 and demonstrated that both Triton-soluble and -insoluble NF-H subunits exhibit an apparent molecular weight of 200 kDa. Incorporation of radiolabeled phosphate into Triton-soluble NF-H following incubation of intact NB2a/d1 cells with 32P-orthophosphate confirmed that the Triton-soluble form of NF-H is a phosphoprotein. Most NF-H subunits in the Triton-soluble fraction sedimented after centrifugation at 100,000 g for 1 h, indicating that they may be present as oligomers. The implications of these data for the development of neurofibrillary pathology are discussed.


Asunto(s)
Proteínas de Filamentos Intermediarios/metabolismo , Neuronas/metabolismo , Células Tumorales Cultivadas/metabolismo , Animales , Línea Celular , Epítopos , Técnicas Inmunológicas , Ratones , Peso Molecular , Neuroblastoma , Proteínas de Neurofilamentos , Octoxinol , Fosforilación , Polietilenglicoles
20.
Proc Natl Acad Sci U S A ; 85(16): 6182-6, 1988 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-2457908

RESUMEN

Monoclonal antibodies to the A4 amyloid polypeptide were used in immunocytochemical staining of the Alzheimer disease prefrontal cortex. Analysis of the resulting staining patterns allowed us to evaluate the amounts and distribution of amyloid-protein deposits exclusive of other senile-plaque components. Previously unappreciated infra-structural details of amyloid in the Alzheimer disease brain became accessible through computer-enhanced imaging procedures. Four discrete morphologic classes of amyloid deposits were observed and classified as punctate, macular, ring, and ring-with-core configurations. Computer imaging indicated that all four classes of immunostained deposits contain internal gradients of density. The classes were nonuniformly distributed with regard to size and location within cortical laminae. Our results support two separate but complementary hypotheses concerning the molecular neuropathology of Alzheimer disease in the prefrontal cortex. (i) Irrespective of cortical layer or morphology, density-gradient analyses suggest that amyloid deposits are elaborated through molecular and cellular events that may involve diffusion or coalescence of the A4 polypeptide. (ii) The distribution and morphology of prefrontal cortical amyloid deposits may be dependent upon underlying laminar-specific structures of the neocortex.


Asunto(s)
Enfermedad de Alzheimer/metabolismo , Amiloide/análisis , Anticuerpos Monoclonales , Corteza Cerebral/análisis , Epítopos/análisis , Aumento de la Imagen , Amiloide/inmunología , Humanos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA